


Asymmetric Organocatalytic Sulfa-Michael Addition to Enone Diesters

Jennifer L. Fulton, Matthew A. Horwitz, Ericka L. Bruske, and Jeffrey S. Johnson*

Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-3290, United States

Supporting Information

ABSTRACT: An asymmetric sulfa-Michael addition of alkyl thiols to enone diesters is reported. The reaction is catalyzed by a bifunctional triarylaminophosphorane-thiourea organocatalyst and provides a range of α -sulfaketones in high yields and enantioselectivities. Leveraging the *gem*-diester functional handle via a subsequent diastereotopic group discrimination generates functionalized lactones with three contiguous stereocenters.



The conjugate addition of heteroatom nucleophiles to prochiral Michael acceptors offers an atom-economical entry into diverse scaffolds with concomitant construction of stereochemical complexity. The application of this reaction manifold to the installation of sulfur in organic frameworks has largely been driven by sulfur's prominence in bioactive molecules¹ and the established utility of thiol- and sulfide-derived functional handles.² To that end, noteworthy advances have been made toward the development of the asymmetric sulfa-Michael reaction using a variety of catalytic systems.³ To advance the art, we sought to expand the range of products accessible through this reaction by studying substrates bearing multiple electrophilic sites on the Michael acceptor. Previous efforts in this direction have demonstrated that Michael acceptors possessing vicinal ester and ketone functionalities (γ -oxo acrylates) give addition exclusively at the ester α -carbon, and achieving high stereoselectivities remains challenging (Scheme 1a).⁴ We viewed this shortcoming of cinchona alkaloid-based catalysts as an opportunity to explore organo-superbase catalysts for this transformation. Recently, the Dixon group developed a *tert*-leucine and phenylglycine-derived triarylaminophosphorane catalyst which promoted the enantioselective addition of alkyl thiols to unactivated α,β -unsaturated esters (Scheme 1b).⁵ In addition, phenylglycine-based triarylaminophosphorane catalyst C1, also developed by the Dixon group,⁶ was found to mediate the addition of nitroalkanes to enone diesters with high regio- and stereoselectivity (Scheme 1c).⁷ By employing this catalyst system, we sought to overcome the challenges of a highly regio- and enantioselective addition of sulfur nucleophiles to acylidene malonates (Scheme 1d).

We began our studies by screening a number of catalysts (see the Supporting Information) and found that organocatalyst C1 chemoselectively added thiol 2a to acylidene malonate 1 to provide sulfide 3a in 97:3 er and 93% yield (Table 1). With our optimized conditions in hand, we first examined the scope of the thiol nucleophile. We observed similar reaction outcomes with branched alkyl thiols (2b–c) as well as linear alkyl thiols

(2d–e), although enantioselectivity was slightly diminished in the latter cases. Benzyl thiols also proved to be competent reaction partners, although it was important to use fewer equivalents of the thiol to maintain good yields and stereoselectivities (3f–3i).⁸ Employing benzyl thiol 2f, the desired product (3f) was obtained in 91:9 er and 90% yield. Probing the impact of various *para*-substituents on the aromatic ring of the benzyl thiol, electron-withdrawing groups led to an increase in enantioselectivity (2g), while electron-donating groups had the opposite effect (2h–i).

Next, we investigated the scope of enone diesters that could be employed in this reaction (Table 2). Enone diesters bearing an electron-releasing acyl substituent (1j–k, 4-methoxy, 3-methoxy, piperonyl) provided the desired products in excellent yield and enantioselectivity regardless of substitution pattern. Halogen-substituted arenes (1m–o) were similarly successful under these reaction conditions, as were other electron-poor enone diesters (1p–q). Cyclopropyl enone diester 1r provided the desired product (3r) in 96% yield, although the enantioselectivity was lowered to 83.5:16.5 er. An exploration of heteroaromatic enone diesters revealed that furan 3s, thiophene 3t, and pyridine 3u could all be obtained in good yield and enantioselectivity. When examining the scalability of this transformation, we observed that on a 1 g scale thiol 2a added to the acylidene malonate to afford 1.21 g of α -sulfaketone 3a without any negative impact on yield or stereoselectivity (Scheme 2).

Seeking to explore the synthetic utility of these products, we developed a two-step local desymmetrization that takes advantage of the diastereotopic ester groups (Scheme 3).⁹ Beginning with enantioenriched thioether 3a, reduction of the ketone with sodium borohydride¹⁰ provided the *syn*-hydroxy sulfide 4a in >20:1 dr and 89% yield. Subsequent acid-

Received: January 2, 2018


Published: March 7, 2018




Scheme 1. Asymmetric Conjugate Addition Reactions

(a) Prior art (Kowalczyk, 2014):

sulfa-Michael addition to 4-oxo-butenates




(b) Prior art (Dixon, 2017):

sulfa-Michael addition to α,β -unsaturated esters


(c) Prior art (Johnson, 2017):

conjugate addition of nitroalkanes to enone diesters



(d) Current work:

sulfa-Michael addition to functionalized enone diesters



promoted cyclization provided lactone **5a** in >20:1 dr and 70% yield. Analogous results were obtained using benzyl thioether **3f**, with both the reduction and lactonization proceeding in good diastereoselectivity and yield. Finally, an X-ray diffraction study revealed the absolute and relative stereochemistry of lactone **5f**.¹¹

In conclusion, we have developed an asymmetric organocatalyzed addition of alkyl thiols to enone diesters with unique regioselectivity that enables access to an unexplored class of enantioenriched sulfa-Michael adducts. The diester products were further manipulated via diastereoselective reduction and subsequent diastereotopic group selection to form stereochemically dense lactone products.

■ EXPERIMENTAL SECTION

General Comments. Nuclear magnetic resonance spectra (¹H NMR, ¹³C NMR, ¹⁹F NMR) were recorded at the following frequencies: ¹H NMR at 400 or 600 MHz, ¹³C NMR at 101 or 151 MHz, ¹⁹F NMR at 376 MHz with solvent resonance as the internal standard (¹H NMR: CDCl₃ at 7.26 ppm and ¹³C NMR: CDCl₃ at 77.0 ppm). ¹H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, br s = broad singlet, d = doublet, dd = doublet of doublet, t = triplet, m = multiplet, app t = apparent triplet), coupling constants (Hz), and integration. High resolution mass spectra were obtained using a linear trap quadrupole Fourier transform (LTQ-FT) spectrometer. TLC visualization was accomplished using UV


Table 1. Asymmetric Conjugate Addition of Alkyl Thiols to Enone Diester **1a**^a

1a (E = CO ₂ ^t Bu)	2	3
3a 97:3 er 93% yield	3b 94:6 er 95% yield	3c 96:4 er 95% yield
3d 91:9 er 94% yield	3e 92:8 er 96% yield	3f 91:9 er 90% yield
3g 93:7 er 89% yield	3h 89:11 er 89% yield	3i 89.5:11.5 er 86% yield

^aAll of the reactions were conducted on a 0.1 mmol scale using 1.5–5.5 equiv of alkyl thiol **2** (see the Experimental Section for specific conditions). Isolated yields are shown. All yields and er values are the average of two trials.


light, phosphomolybdic acid in ethanol, or aqueous ceric ammonium nitrate solution. HPLC analyses were carried out using Daicel Chiralpak IA, IC, and AD columns. Yields refer to isolated yields after flash column chromatography. Since all asymmetric trial results are the averages of two trials, the stereoisomer ratios listed in the paper may not exactly match those represented in the NMR and HPLC data below. Diethyl ether (Et₂O) was passed through a column of neutral alumina under nitrogen prior to use. The thiols employed were obtained from commercial sources and used as received. Enone diesters were prepared according to a literature procedure.⁷ Triaryliminophosphorane catalysts **C1**–**C3** were prepared according to a literature procedure.^{6a} Racemic samples were obtained by employing the general procedure and using 2-*tert*-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP) in place of organocatalyst **C1**.

General Procedure for the Asymmetric Conjugate Addition of Alkyl Thiols. A flame-dried test tube was charged sequentially with enone diester **1** (0.1 mmol, 1.0 equiv) and Et₂O (1.0 mL). The reaction was stirred at –60 °C in a cryogenic cooling apparatus for 15 min, then triaryliminophosphorane catalyst **C1** (0.01 mmol, 0.10 equiv) was added, followed by thiol **2** (see below for thiol identity and equivalents). The reaction was stirred at –60 °C for 24 h, then quenched with a TFA solution in toluene (50 μ L, 0.5 M solution) at the same temperature. The solvent was removed *in vacuo*, and the crude material was purified using flash column chromatography with 97.5/2.5 hexanes/EtOAc unless otherwise noted.

Table 2. Asymmetric Conjugate Addition of 2-Propanethiol to Enone Diester 1^a


^aAll of the reactions were conducted on a 0.1 mmol scale using 5.4 equiv of alkyl thiol **2a**. Isolated yields are shown. All yields and er values are the average of two trials.

Scheme 2. Gram-Scale Asymmetric Sulfa-Michael Reaction



Gram-Scale Asymmetric Conjugate Addition Reaction with Propane-2-thiol. A flame-dried test tube was charged sequentially with enone diester (1.00 g, 3.01 mmol, 1.0 equiv) and Et₂O (30 mL). The reaction was stirred at -60 °C in a cryogenic cooling apparatus for 15 min, then triaryliminophosphorane catalyst **C1** (201 mg, 0.30 mmol, 0.10 equiv) was added, followed by propane-2-thiol (1.51 mL, 16.3 mmol, 5.38 equiv). The reaction was stirred at -60 °C for 24 h, then quenched with a TFA solution in toluene (1.5 mL, 0.5 M solution) at the same temperature. The solvent was removed *in vacuo*, and the crude material was purified using flash column chromatog-

Scheme 3. Local Desymmetrization via Diastereoselective Reduction and Lactonization



raphy with 97.5/2.5 hexanes/EtOAc to yield 1.21 g (93%) of a low-melting white solid in 97:3 er.

Di-tert-butyl (S)-2-(1-(Isopropylthio)-2-oxo-2-phenylethyl)-malonate (3a). The title compound was prepared using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv) according to the general procedure. Low-melting white solid (38.3 mg, 0.093 mmol, 93%); ¹H NMR (600 MHz, CDCl₃) δ 8.05 (d, *J* = 7.9 Hz, 2H); 7.58 (t, *J* = 7.3 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 2H), 4.76 (d, *J* = 11.6 Hz, 1H), 4.17 (d, *J* = 11.6 Hz, 1H), 2.96–2.89 (m, 1H), 1.55 (s, 9H), 1.39 (s, 9H), 1.23 (t, *J* = 6.8 Hz, 3H), 1.10 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 194.8, 167.0, 166.9, 135.9, 133.0, 128.7, 128.6, 82.4, 82.2, 55.8, 45.7, 34.6, 28.0, 27.8, 24.8, 24.2. IR (thin film) ν 3430, 2977, 2360, 1729, 1679, 1369, 1299, 1252, 1140, 690 cm⁻¹. HRMS (ESI): Calcd For C₂₂H₃₂O₅SN⁺ ([M + Na⁺]): 431.1868, found 431.1858. HPLC Chiralpak IC column, Hex/PrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 11.5 min, *t*_R (major) 15.4 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.41. [α]_D²⁵ = -65.9 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(tert-Butylthio)-2-oxo-2-phenylethyl)-malonate (3b). The title compound was prepared using 2-methylpropane-2-thiol (0.06 mL, 0.53 mmol, 5.32 equiv) according to the general procedure. White solid (43.5 mg, 0.100 mmol, 100%), mp 76–78 °C (decomp); ¹H NMR (600 MHz, CDCl₃) δ 8.06 (d, *J* = 7.7 Hz, 2H), 7.56 (t, *J* = 7.3 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 2H), 4.76 (d, *J* = 11.8 Hz, 1H), 4.17 (d, *J* = 11.8 Hz, 1H), 1.55 (s, 9H), 1.38 (s, 9H), 1.18 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 198.2, 167.1 (2C), 136.9, 132.7, 129.1, 128.4, 82.5, 82.1, 57.0, 45.6, 45.4, 31.5, 28.0, 27.8. IR (thin film) ν 2979, 2360, 1739, 1682, 1368, 1290, 1252, 1138, 855, 695 cm⁻¹. HRMS (ESI): Calcd For C₂₃H₃₄O₅SN⁺ ([M + Na⁺]): 445.2025, found 445.2016. HPLC Chiralpak IC column, Hex/PrOH = 96:4, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 7.6 min, *t*_R (major) 10.4 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.42. [α]_D²⁵ = -89.2 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(Cyclohexylthio)-2-oxo-2-phenylethyl)malonate (3c). The title compound was prepared using cyclohexanethiol (0.06 mL, 0.49 mmol, 4.90 equiv) according to the general procedure. White solid (43.7 mg, 0.097 mmol, 97%), mp 53–55 °C (decomp); ¹H NMR (600 MHz, CDCl₃) δ 8.04 (d, *J* = 7.9 Hz, 2H), 7.57 (t, *J* = 7.3 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 2H), 4.76 (d, *J* = 11.6 Hz, 1H), 4.15 (d, *J* = 11.6 Hz, 1H), 2.71–2.67 (m, 1 H), 1.95–1.89 (m, 1H), 1.73–1.64 (m, 2H), 1.63–1.57 (m, 1H), 1.55 (s, 9H), 1.53–1.48 (m, 1H), 1.38 (s, 9H), 1.32–1.26 (m, 2H), 1.25–1.19 (m, 1H), 1.18–1.11 (m, 2H); ¹³C NMR (151 MHz, CDCl₃) δ 194.7, 167.0, 166.9, 135.9, 133.0, 128.7, 128.6, 82.4, 82.1, 55.8, 45.3, 42.4, 34.8, 34.4, 28.0, 27.8, 26.1, 26.0, 25.4. IR (thin film) ν 2978, 2931, 2853, 2360, 1741, 1680, 1369, 1299, 1139, 857 cm⁻¹. HRMS (ESI): Calcd For C₂₅H₃₆O₅SNa⁺ ([M + Na]⁺): 471.2181, found 471.2171. HPLC Chiralpak IC column, Hex/ⁱPrOH = 96:4, flow rate = 1.0 mL/min, λ = 230 nm, *t*_R (minor) 6.8 min, *t*_R (major) 9.8 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.39. [α]_D²⁵ = -64.3 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(Ethylthio)-2-oxo-2-phenylethyl)malonate (3d). The title compound was prepared using ethanethiol (0.04 mL, 0.56 mmol, 5.52 equiv) according to the general procedure. Clear oil (36.5 mg, 0.092 mmol, 92%); ¹H NMR (600 MHz, CDCl₃) δ 8.05 (d, *J* = 7.9 Hz, 2H), 7.58 (t, *J* = 7.3 Hz, 1H), 7.50 (t, *J* = 7.5 Hz), 4.73 (d, *J* = 11.5 Hz, 1H), 4.14 (d, *J* = 11.5 Hz, 1H), 2.63–2.58 (m, 1H), 2.39–2.33 (m, 1H), 1.55 (s, 9H), 1.39 (s, 9H), 1.14 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.1, 167.0, 166.8, 135.5, 133.1, 128.7, 128.6, 82.5, 82.2, 54.8, 44.9, 28.0, 27.8, 22.9, 13.8. IR (thin film) ν 3431, 2978, 1741, 1679, 1369, 1300, 1259, 1140, 856, 689 cm⁻¹. HRMS (ESI): Calcd For C₂₁H₃₀O₅SNa⁺ ([M + Na]⁺): 417.1708, found 417.1701. HPLC Chiralpak IC column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 9.5 min, *t*_R (major) 14.8 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.39. [α]_D²⁵ = -44.2 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(2-Oxo-2-phenyl-1-(propylthio)ethyl)malonate (3e). The title compound was prepared using propane-1-thiol (0.05 mL, 0.54 mmol, 5.36 equiv) according to the general procedure. Clear oil (39.5 mg, 0.096 mmol, 96%); ¹H NMR (600 MHz, CDCl₃) δ 8.05 (d, *J* = 7.7 Hz, 2H), 7.58 (t, *J* = 7.3 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 2H), 4.73 (d, *J* = 11.5 Hz, 1H), 4.13 (d, *J* = 11.5 Hz, 1H), 2.58–2.53 (m, 1H), 2.33–2.29 (m, 1H), 1.55 (s, 9H), 1.52–1.46 (m, 2H), 1.39 (s, 9H), 0.90 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.2, 166.9, 166.8, 135.5, 133.0, 128.7, 128.6, 82.4, 82.1, 54.8, 44.7, 30.6, 28.0, 27.8, 22.3, 13.6. IR (thin film) ν 3431, 2978, 2360, 1740, 1680, 1369, 1299, 1139, 856, 668 cm⁻¹. HRMS (ESI): Calcd For C₂₂H₃₂O₅SNa⁺ ([M + Na]⁺): 431.1868, found 431.1858. HPLC Chiralpak IC column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 6.6 min, *t*_R (major) 9.4 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.41. [α]_D²⁵ = -54.0 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(Benzylthio)-2-oxo-2-phenylethyl)malonate (3f). The title compound was prepared using phenylmethanethiol (0.02 mL, 0.17 mmol, 1.71 equiv) according to the general procedure. Low-melting white solid (40.4 mg, 0.091 mmol, 91%); ¹H NMR (600 MHz, CDCl₃) δ 7.98 (d, *J* = 7.9 Hz, 2H), 7.58 (t, *J* = 7.4 Hz, 1H), 7.47 (t, *J* = 7.6 Hz, 2H), 7.29–7.22 (m, 5H), 4.79 (d, *J* = 11.4 Hz, 1H), 4.26 (d, *J* = 11.4 Hz, 1H), 3.86 (d, *J* = 11.8 Hz, 1H), 3.55 (d, *J* = 11.8 Hz, 1H), 1.58 (s, 9H), 1.40 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 193.2, 166.9 (2C), 136.2, 135.4, 133.1, 129.4, 128.7, 128.6, 128.5, 127.3, 82.6, 82.3, 55.0, 45.3, 33.7, 28.0, 27.8. IR (thin film) ν 3431, 2978, 2360, 1727, 1678, 1369, 1300, 1252, 1157, 691 cm⁻¹. HRMS (ESI): Calcd For C₂₆H₃₂O₅SNa⁺ ([M + Na]⁺): 479.1868, found 479.1858. HPLC Chiralpak IC column, Hex/ⁱPrOH = 99:1, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (major) 10.8 min, *t*_R (minor) 12.3 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.36. [α]_D²⁵ = -50.6 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(4-Chlorobenzyl)thio)-2-oxo-2-phenylethylmalonate (3g). The title compound was prepared using (4-chlorophenyl)methanethiol (0.02 mL, 0.15 mmol, 1.51 equiv) according to the general procedure. Low-melting white solid (44.4 mg, 0.089 mmol, 89%); ¹H NMR (600 MHz, CDCl₃) δ 7.94 (d, *J* = 7.9 Hz, 2H), 7.58 (t, *J* = 7.4 Hz, 1H), 7.47 (t, *J* = 7.7 Hz, 2H), 7.21 (d, *J* = 8.3 Hz, 2H), 7.15 (d, *J* = 8.2 Hz, 2H), 4.76 (d, *J* = 11.5 Hz,

1H), 4.23 (d, *J* = 11.5 Hz, 1H), 3.81 (d, *J* = 12.1 Hz, 1H), 3.51 (d, *J* = 12.1 Hz, 1H), 1.57 (s, 9H), 1.38 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 193.2, 166.8 (2C), 135.3, 134.9, 133.2, 133.1, 130.7, 128.7, 128.6 (2C), 82.7, 82.4, 55.0, 45.1, 33.1, 28.0, 27.8. IR (thin film) ν 3431, 2979, 2360, 1739, 1678, 1491, 1369, 1301, 1140, 690 cm⁻¹. HRMS (ESI): Calcd For C₂₆H₃₁ClO₅SNa⁺ ([M + Na]⁺): 513.1479, found 513.1469. HPLC Chiralpak IC column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (major) 9.1 min, *t*_R (minor) 12.2 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.41. [α]_D²⁵ = -54.6 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(4-Methoxybenzyl)thio)-2-oxo-2-phenylethylmalonate (3h). The title compound was prepared using (4-methoxyphenyl)methanethiol (0.03 mL, 0.21 mmol, 2.15 equiv) according to the general procedure. The crude material was purified via flash column chromatography using a gradient from 97.5/2.5 hexanes/EtOAc to 95/5 hexanes/EtOAc. Low-melting white solid (45.2 mg, 0.094 mmol, 94%); ¹H NMR (600 MHz, CDCl₃) δ 7.97 (d, *J* = 7.9 Hz, 2H), 7.58 (t, *J* = 7.3 Hz, 1H), 7.46 (t, *J* = 7.6 Hz, 2H), 7.14 (d, *J* = 8.4 Hz, 2H), 6.79 (d, *J* = 8.4 Hz, 2H), 4.76 (d, *J* = 11.5 Hz, 1H), 4.26 (d, *J* = 11.5 Hz, 1H), 3.82 (d, *J* = 11.8 Hz, 1H), 3.78 (s, 3H), 3.50 (d, *J* = 11.8 Hz, 1H), 1.58 (s, 9H), 1.40 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 193.2, 166.9 (2C), 158.8, 135.4, 133.0, 130.5, 128.7, 128.6, 128.0, 113.9, 82.5, 82.3, 55.2, 54.5, 45.3, 33.2, 28.0, 27.8. IR (thin film) ν 3431, 2978, 2360, 1777, 1738, 1512, 1251, 1139, 833, 690 cm⁻¹. HRMS (ESI): Calcd For C₂₇H₃₄O₆SNa⁺ ([M + Na]⁺): 509.1974, found 509.1967. HPLC Chiralpak IC column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (major) 14.8 min, *t*_R (minor) 18.1 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.25. [α]_D²⁵ = -49.9 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(4-(tert-Butyl)benzyl)thio)-2-oxo-2-phenylethylmalonate (3i). The title compound was prepared using (4-tert-butylphenyl)methanethiol (0.03 mL, 0.16 mmol, 1.60 equiv) according to the general procedure. Clear oil (44.4 mg, 0.086 mmol, 86%); ¹H NMR (600 MHz, CDCl₃) δ 7.98 (d, *J* = 7.8 Hz, 2H), 7.58 (t, *J* = 7.4 Hz, 1H), 7.47 (t, *J* = 7.5 Hz, 2H), 7.28 (d, *J* = 7.9 Hz, 2H), 7.15 (d, *J* = 7.9 Hz, 2H), 4.79 (d, *J* = 11.4 Hz, 1H), 4.26 (d, *J* = 11.5 Hz, 1H), 3.86 (d, *J* = 11.8 Hz, 1H), 3.53 (d, *J* = 11.7 Hz, 1H), 1.59 (s, 9H), 1.41 (s, 9H), 1.30 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 193.2, 166.9 (2C), 150.2, 135.5, 133.0 (2C), 129.0, 128.7, 128.6, 125.4, 82.5, 82.3, 54.9, 45.4, 34.5, 33.2, 31.3, 28.0, 27.8. IR (thin film) ν 3431, 2970, 2360, 1728, 1678, 1368, 1300, 1253, 1139, 851 cm⁻¹. HRMS (ESI): Calcd For C₃₀H₄₀O₅SNa⁺ ([M + Na]⁺): 535.2494, found 535.2491. HPLC Chiralpak AD column, Hex/ⁱPrOH = 99:1, flow rate = 1.0 mL/min, λ = 254 nm, *t*_R (minor) 7.7 min, *t*_R (major) 9.5 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.39. [α]_D²⁵ = -48.3 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(Isopropylthio)-2-(4-methoxyphenyl)-2-oxoethyl)malonate (3j). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). The crude material was purified via flash column chromatography using a gradient from 97.5/2.5 hexanes/EtOAc to 95/5 hexanes/EtOAc. Clear oil (43.6 mg, 0.099 mmol, 99%); ¹H NMR (600 MHz, CDCl₃) δ 8.04 (d, *J* = 8.9 Hz, 2H), 6.97 (d, *J* = 8.9 Hz, 2H), 4.73 (d, *J* = 11.6 Hz, 1H), 4.16 (d, *J* = 11.5 Hz, 1H), 3.89 (s, 3H), 2.97–2.90 (m, 1H), 1.55 (s, 9H), 1.38 (s, 9H), 1.24 (d, *J* = 6.8 Hz, 3H), 1.10 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.5, 167.1, 167.0, 163.5, 131.0, 128.6, 113.8, 82.3, 82.1, 55.8, 55.5, 45.3, 34.4, 28.0, 27.8, 24.8, 24.2. IR (thin film) ν 3431, 2978, 2360, 1739, 1669, 1602, 1369, 1260, 1142, 860 cm⁻¹. HRMS (ESI): Calcd For C₂₃H₃₄O₆SNa⁺ ([M + Na]⁺): 461.1974, found 461.1964. HPLC Chiralpak IA column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (major) 9.8 min, *t*_R (minor) 10.7 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.29. [α]_D²⁵ = -43.7 (*c* = 2.0, CHCl₃).

Di-tert-butyl (S)-2-(1-(Isopropylthio)-2-(3-methoxyphenyl)-2-oxoethyl)malonate (3k). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). The crude material was purified via flash column chromatography using a gradient from 97.5/2.5 hexanes/EtOAc to 95/5 hexanes/EtOAc. Clear oil (42.3 mg, 0.096 mmol, 96%); ¹H NMR (600 MHz, CDCl₃) δ 7.64 (d, *J* = 7.7 Hz, 1H), 7.56 (dd, *J* = 2.4

H₂, 1.6 Hz, 1H), 7.40 (t, *J* = 8.0 Hz, 1H), 7.12 (dd, *J* = 8.2 Hz, 2.6 Hz, 1H), 4.73 (d, *J* = 11.6 Hz, 1H), 4.16 (d, *J* = 11.6 Hz, 1H), 2.96–2.89 (m, 1H), 1.55 (s, 9H), 1.39 (s, 9H), 1.23 (d, *J* = 6.8 Hz, 3H), 1.12 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 194.6, 166.9 (2C), 159.8, 137.3, 129.6, 121.2, 119.5, 113.1, 82.5, 82.2, 55.8, 55.4, 45.7, 34.7, 28.0, 27.8, 24.7, 24.2. IR (thin film) ν 3432, 2978, 2360, 1729, 1679, 1583, 1369, 1288, 1159, 761 cm⁻¹. HRMS (ESI): Calcd For C₂₃H₃₄O₆SN⁺ ([M + Na⁺]): 461.1974, found 461.1963. HPLC Chiralpak IA column, Hex/ⁱPrOH = 96:4, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 8.2 min, *t*_R (major) 12.7 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.35. [α]_D²⁵ = -74.5 (*c* = 2.0, CHCl₃).

Di-*tert*-butyl (S)-2-(2-(Benzo[d][1,3]dioxol-5-yl)-1-(isopropylthio)-2-oxoethyl)malonate (3l). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). The crude material was purified via flash column chromatography using a gradient from 97.5/2.5 hexanes/EtOAc to 95/5 hexanes/EtOAc. Clear oil (42.3 mg, 0.093 mmol, 93%); ¹H NMR (600 MHz, CDCl₃) δ 7.68 (dd, *J* = 8.2 Hz, 1.7 Hz, 1H), 7.51 (d, *J* = 1.7 Hz, 1H), 6.89 (d, *J* = 8.2 Hz, 1H), 6.06 (s, 2H), 4.67 (d, *J* = 11.6 Hz, 1H), 4.14 (d, *J* = 11.5 Hz, 1H), 2.97–2.90 (m, 1H), 1.54 (s, 9H), 1.38 (s, 9H), 1.24 (d, *J* = 6.9 Hz, 3H), 1.11 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.0, 167.0, 166.9, 151.8, 148.1, 130.4, 124.8, 108.7, 108.0, 101.9, 82.4, 82.1, 55.9, 45.4, 34.5, 28.0, 27.8, 24.8, 24.2. IR (thin film) ν 3431, 2978, 1727, 1672, 1442, 1258, 1139, 1038, 850, 734 cm⁻¹. HRMS (ESI): Calcd For C₂₃H₃₃O₇S⁺ ([M + H⁺]): 453.1948, found 453.1940. HPLC Chiralpak IA column, Hex/ⁱPrOH = 95:5, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (major) 5.5 min, *t*_R (minor) 6.2 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.30. [α]_D²⁵ = -51.8 (*c* = 2.0, CHCl₃).

Di-*tert*-butyl (S)-2-(2-(4-Bromophenyl)-1-(isopropylthio)-2-oxoethyl)malonate (3m). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). White solid (46.8 mg, 0.096 mmol, 96%), mp 73–75 °C (decomp); ¹H NMR (600 MHz, CDCl₃) δ 7.92 (d, *J* = 8.6 Hz, 2H), 7.64 (d, *J* = 8.6 Hz, 2H), 4.69 (d, *J* = 11.6 Hz, 1H), 4.15 (d, *J* = 11.6 Hz, 1H), 2.94–2.87 (m, 1H), 1.55 (s, 9H), 1.39 (s, 9H), 1.24 (d, *J* = 6.8 Hz, 3H), 1.09 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.8, 167.0, 166.8, 134.7, 131.9, 130.2, 128.1, 82.6, 82.3, 55.7, 45.7, 34.7, 28.0, 27.8, 24.8, 24.2. IR (thin film) ν 3430, 2978, 2360, 1729, 1679, 1586, 1369, 1309, 1251, 1139 cm⁻¹. HRMS (ESI): Calcd For C₂₂H₃₁BrO₅SN⁺ ([M + Na⁺]): 509.0974, found 509.0963. HPLC Chiralpak IC column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 5.8 min, *t*_R (major) 8.0 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.50. [α]_D²⁵ = -41.3 (*c* = 2.0, CHCl₃).

Di-*tert*-butyl (S)-2-(2-(4-Chlorophenyl)-1-(isopropylthio)-2-oxoethyl)malonate (3n). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). White solid (43.6 mg, 0.098 mmol, 98%), mp 64–66 °C (decomp); ¹H NMR (600 MHz, CDCl₃) δ 7.99 (d, *J* = 8.6 Hz, 2H), 7.47 (d, *J* = 8.6 Hz, 2H), 4.69 (d, *J* = 11.6 Hz, 1H), 4.15 (d, *J* = 11.6 Hz, 1H), 2.94–2.87 (m, 1H), 1.55 (s, 9H), 1.39 (s, 9H), 1.24 (d, *J* = 6.8 Hz, 3H), 1.09 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.6, 167.0, 166.8, 139.4, 134.2, 130.1, 128.9, 82.6, 82.3, 55.7, 45.7, 34.6, 27.9, 27.8, 24.8, 24.2. IR (thin film) ν 3430, 2979, 1740, 1680, 1590, 1369, 1309, 1140, 1093, 861 cm⁻¹. HRMS (ESI): Calcd For C₂₂H₃₁ClO₅SN⁺ ([M + Na⁺]): 465.1479, found 465.1469. HPLC Chiralpak IC column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 5.7 min, *t*_R (major) 7.5 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.47. [α]_D²⁵ = -53.0 (*c* = 2.0, CHCl₃).

Di-*tert*-butyl (S)-2-(2-(4-Fluorophenyl)-1-(isopropylthio)-2-oxoethyl)malonate (3o). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). White solid (39.2 mg, 0.093 mmol, 93%), mp 71–73 °C (decomp); ¹H NMR (600 MHz, CDCl₃) δ 8.10–8.07 (m, 2H), 7.17 (app t, *J* = 8.6 Hz, 2H), 4.71 (d, *J* = 11.6 Hz, 1H), 4.16 (d, *J* = 11.5 Hz, 1H), 2.95–2.88 (m, 1H), 1.55 (s, 9H), 1.39 (s, 9H), 1.24 (d, *J* = 6.8 Hz, 3H), 1.09 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.3, 167.0, 166.8, 165.7 (d, *J* = 254.7 Hz), 132.2 (d, *J* = 3.0 Hz), 131.3 (d, *J* = 9.2 Hz), 115.7 (d, *J* = 21.9 Hz), 82.5, 82.2, 55.7, 45.7, 34.6, 27.9, 27.8, 24.8, 24.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -105.41.

IR (thin film) ν 3431, 2979, 2360, 1728, 1678, 1598, 1369, 1308, 1157, 862 cm⁻¹. HRMS (ESI): Calcd For C₂₂H₃₁FO₅SN⁺ ([M + Na⁺]): 449.1774, found 449.1764. HPLC Chiralpak IC column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 5.6 min, *t*_R (major) 6.8 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.43. [α]_D²⁵ = -70.0 (*c* = 2.0, CHCl₃).

Di-*tert*-butyl (S)-2-(1-(Isopropylthio)-2-(4-nitrophenyl)-2-oxoethyl)malonate (3p). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). Clear oil (42.0 mg, 0.093 mmol, 93%); ¹H NMR (600 MHz, CDCl₃) δ 8.34 (d, *J* = 8.9 Hz, 2H), 8.20 (d, *J* = 8.9 Hz, 2H), 4.70 (d, *J* = 11.5 Hz, 1H), 4.16 (d, *J* = 11.5 Hz, 1H), 2.94–2.87 (m, 1H), 1.56 (s, 9H), 1.41 (s, 9H), 1.24 (d, *J* = 6.8 Hz, 3H), 1.10 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.1, 167.1, 166.6, 150.2, 141.1, 129.7, 123.8, 82.9, 82.5, 55.6, 46.4, 34.9, 27.9, 27.8, 24.8, 24.1. IR (thin film) ν 3439, 2978, 2931, 1738, 1685, 1530, 1307, 1139, 850, 702 cm⁻¹. HRMS (ESI): Calcd For C₂₂H₃₁NO₅SN⁺ ([M + Na⁺]): 476.1719, found 476.1712. HPLC Chiralpak IC column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 9.6 min, *t*_R (major) 13.0 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.39. [α]_D²⁵ = -46.6 (*c* = 2.0, CHCl₃).

Di-*tert*-butyl (S)-2-(2-(4-Cyanophenyl)-1-(isopropylthio)-2-oxoethyl)malonate (3q). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). The crude material was purified via flash column chromatography using a gradient from 97.5/2.5 hexanes/EtOAc to 95/5 hexanes/EtOAc. White solid (38.8 mg, 0.091 mmol, 91%), mp 83–85 °C (decomp); ¹H NMR (600 MHz, CDCl₃) δ 8.13 (d, *J* = 8.4 Hz, 2H), 7.80 (d, *J* = 8.5 Hz, 2H), 4.67 (d, *J* = 11.6 Hz, 1H), 4.15 (d, *J* = 11.6 Hz, 1H), 2.92–2.86 (m, 1H), 1.55 (s, 9H), 1.40 (s, 9H), 1.23 (d, *J* = 6.8 Hz, 3H), 1.09 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 193.3, 167.0, 166.6, 139.4, 132.4, 129.1, 118.0, 116.1, 82.8, 82.5, 55.6, 46.1, 34.8, 27.9, 27.8, 24.8, 24.1. IR (thin film) ν 2978, 2231, 1727, 1685, 1369, 1298, 1162, 1140, 866, 755 cm⁻¹. HRMS (ESI): Calcd For C₂₃H₃₁NO₅SN⁺ ([M + Na⁺]): 456.1821, found 456.1815. HPLC Chiralpak IC column, Hex/ⁱPrOH = 96:4, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor) 11.0 min, *t*_R (major) 12.9 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.30. [α]_D²⁵ = -51.0 (*c* = 2.0, CHCl₃).

Di-*tert*-butyl (S)-2-(2-(Cyclopropyl)-1-(isopropylthio)-2-oxoethyl)malonate (3r). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). Low-melting white solid (33.2 mg, 0.092 mmol, 92%); ¹H NMR (600 MHz, CDCl₃) δ 4.07 (d, *J* = 11.6 Hz, 1H), 3.88 (d, *J* = 11.6 Hz, 1H), 2.98–2.91 (m, 1H), 2.26–2.22 (m, 1H), 1.51 (s, 9H), 1.43 (s, 9H), 1.31 (d, *J* = 6.8 Hz, 3H), 1.22 (d, *J* = 6.8 Hz, 3H), 1.13–1.09 (m, 1H), 1.09–1.05 (m, 1H), 1.01–0.96 (m, 2H); ¹³C NMR (151 MHz, CDCl₃) δ 204.7, 166.7, 166.7, 82.2, 82.0, 55.3, 51.2, 34.8, 27.9, 27.8, 24.8, 24.1, 19.5, 12.1, 11.2. IR (thin film) ν 3445, 2979, 2931, 1732, 1609, 1369, 1255, 1141, 1054, 851 cm⁻¹. HRMS (ESI): Calcd For C₁₉H₃₂O₅SN⁺ ([M + Na⁺]): 395.1868, found 395.1858. HPLC Chiralpak AD column, Hex/ⁱPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (major) 5.0 min, *t*_R (minor) 10.5 min. TLC (10/90 EtOAc/hexanes): *R*_f = 0.40. [α]_D²⁵ = -103.6 (*c* = 1.5, CHCl₃).

Di-*tert*-butyl (S)-2-(2-(Furan-2-yl)-1-(isopropylthio)-2-oxoethyl)malonate (3s). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). The crude material was purified via flash column chromatography using a gradient from 97.5/2.5 hexanes/EtOAc to 95/5 hexanes/EtOAc. White solid (36.9 mg, 0.091 mmol, 91%), mp 103–105 °C (decomp); ¹H NMR (600 MHz, CDCl₃) δ 7.62 (d, *J* = 0.9 Hz, 1H), 7.32 (d, *J* = 3.5 Hz, 1H), 6.58 (dd, *J* = 3.5 Hz, 1.6 Hz, 1H), 4.59 (d, *J* = 11.8 Hz, 1H), 4.11 (d, *J* = 11.8 Hz, 1H), 3.10–3.03 (m, 1H), 1.54 (s, 9H), 1.38 (s, 9H), 1.26 (d, *J* = 6.8 Hz, 3H), 1.19 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 183.9, 166.8, 166.7, 151.3, 146.3, 118.0, 112.6, 82.5, 82.2, 55.3, 45.8, 35.1, 27.9, 27.8, 24.4, 24.0. IR (thin film) ν 3430, 2979, 2360, 1737, 1659, 1468, 1366, 1311, 1165, 1138 cm⁻¹. HRMS (ESI): Calcd For C₂₀H₃₀O₆SN⁺ ([M + Na⁺]): 421.1661, found 421.1650. HPLC Chiralpak IC column, Hex/ⁱPrOH = 96:4, flow rate = 1.0 mL/min, λ = 210 nm, *t*_R (minor)

12.1 min, t_R (major) 17.5 min. TLC (10/90 EtOAc/hexanes): $R_f = 0.27$. $[\alpha]_D^{25} = -56.2$ ($c = 2.0$, CHCl_3).

Di-tert-butyl (S)-2-(2-(Furan-2-yl)-1-(isopropylthio)-2-oxoethyl)-malonate (3t). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). The crude material was purified via flash column chromatography using a gradient from 97.5/2.5 hexanes/EtOAc to 95/5 hexanes/EtOAc. White solid (39.5 mg, 0.095 mmol, 95%), mp 71–73 °C (decomp); ^1H NMR (600 MHz, CDCl_3) δ 7.86 (dd, $J = 3.8$ Hz, 1.1 Hz, 1H), 7.67 (dd, $J = 4.9$ Hz, 1.0 Hz, 1H), 7.17 (dd, $J = 4.9$ Hz, 3.8 Hz, 1H), 4.58 (d, $J = 11.6$ Hz, 1H), 4.13 (d, $J = 11.6$ Hz, 1H), 3.08–2.99 (m, 1H), 1.55 (s, 9H), 1.38 (s, 9H), 1.27 (d, $J = 6.8$ Hz, 3H), 1.16 (d, $J = 6.8$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 187.9, 166.8, 166.7, 142.4, 133.8, 132.4, 128.2, 82.5, 82.2, 55.7, 47.1, 34.7, 27.9, 27.8, 24.7, 24.2. IR (thin film) ν 3431, 2978, 1730, 1659, 1415, 1369, 1304, 1161, 849, 724 cm^{-1} . HRMS (ESI): Calcd For $\text{C}_{20}\text{H}_{30}\text{O}_5\text{S}_2\text{Na}^+$ ($[\text{M} + \text{Na}^+]$): 437.1433, found 437.1423. HPLC Chiralpak IC column, Hex/ $\text{PrOH} = 98:2$, flow rate = 1.0 mL/min, $\lambda = 210$ nm, t_R (minor) 10.7 min, t_R (major) 15.7 min. TLC (10/90 EtOAc/hexanes): $R_f = 0.33$. $[\alpha]_D^{25} = -60.5$ ($c = 2.0$, CHCl_3).

Di-tert-butyl (S)-2-(1-(isopropylthio)-2-oxo-2-(pyridin-4-yl)ethyl)-malonate (3u). The title compound was prepared according to the general procedure using propane-2-thiol (0.05 mL, 0.54 mmol, 5.38 equiv). The crude material was purified via flash column chromatography using a gradient from 90/10 hexanes/EtOAc to 85/15 hexanes/EtOAc. White solid (37.3 mg, 0.090 mmol, 90%), mp 69–71 °C (decomp); ^1H NMR (600 MHz, CDCl_3) δ 8.82 (d, $J = 5.9$ Hz, 2H), 7.82 (dd, $J = 4.4$ Hz, 1.6 Hz, 2H), 4.64 (d, $J = 11.6$ Hz, 1H), 4.13 (d, $J = 11.6$ Hz, 1H), 2.92–2.85 (m, 1H), 1.54 (s, 9H), 1.40 (s, 9H), 1.23 (d, $J = 6.8$ Hz, 3H), 1.10 (d, $J = 6.8$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 193.8, 167.0, 166.5, 150.8, 142.5, 121.7, 82.9, 82.5, 55.4, 46.1, 34.9, 27.9, 27.8, 24.7, 24.1. IR (thin film) ν 3431, 2979, 2360, 1728, 1691, 1369, 1301, 1141, 861, 667 cm^{-1} . HRMS (ESI): Calcd For $\text{C}_{21}\text{H}_{32}\text{NO}_5\text{S}^+$ ($[\text{M} + \text{H}^+]$): 410.2002, found 410.1990. HPLC Chiralpak IA column, Hex/ $\text{PrOH} = 98:2$, flow rate = 1.0 mL/min, $\lambda = 225$ nm, t_R (major) 7.2 min, t_R (minor) 8.5 min. TLC (25/75 EtOAc/hexanes): $R_f = 0.32$. $[\alpha]_D^{25} = -65.5$ ($c = 2.0$, CHCl_3).

General Procedure for the Reduction of 3. A vial under a N_2 atmosphere was charged with α -sulfaketone 3 (0.15 mmol, 1.0 equiv), followed by MeOH (1.5 mL). The reaction mixture was cooled to -20 °C, NaBH_4 (10.3 mg, 1.75 equiv) was added, and stirring was continued at -20 °C. After quenching with 1 M HCl (1.5 mL), the product was extracted with DCM (3 \times), dried with Na_2SO_4 , and concentrated *in vacuo*. The crude material was purified via column chromatography using a gradient from 97.5/2.5 hexanes/EtOAc to 95/5 hexanes/EtOAc.

Di-tert-butyl 2-((1S,2S)-2-Hydroxy-1-(isopropylthio)-2-phenylethyl)malonate (4a). The product was synthesized according to the general procedure, and quenched after 1 h. White solid (53.7 mg, 0.131 mmol, 87%), mp 85–87 °C (decomp); ^1H NMR (600 MHz, CDCl_3) δ 7.46 (d, $J = 7.5$ Hz, 2H), 7.37 (t, $J = 7.6$ Hz, 2H), 7.29 (t, $J = 7.3$ Hz, 1H), 4.89 (d, $J = 3.4$ Hz, 1H), 3.54–3.49 (m, 2H), 2.39–2.32 (m, 1H), 1.52 (s, 9H), 1.51 (s, 9H), 1.11 (d, $J = 6.7$ Hz, 3H), 0.95 (d, $J = 6.7$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 167.7, 167.0, 142.1, 128.2, 127.6, 126.1, 82.6, 82.0, 76.8, 73.0, 57.2, 53.5, 37.4, 28.0, 23.3 (2C). IR (thin film) ν 3434, 2979, 2089, 1725, 1645, 1454, 1628, 1251, 1155, 1139 cm^{-1} . HRMS (ESI): Calcd For $\text{C}_{22}\text{H}_{34}\text{O}_5\text{SNa}^+$ ($[\text{M} + \text{Na}^+]$): 433.2025, found 433.2012. HPLC Chiralpak IA column, Hex/ $\text{PrOH} = 97:3$, flow rate = 1.0 mL/min, $\lambda = 210$ nm, t_R (major) 7.3 min, t_R (minor) 8.8 min. TLC (10/90 EtOAc/hexanes): $R_f = 0.29$. $[\alpha]_D^{25} = -7.33$ ($c = 0.75$, CHCl_3).

Di-tert-butyl 2-((1S,2S)-1-(Benzylthio)-2-hydroxy-2-phenylethyl)-malonate (4f). The product was synthesized according to the general procedure, and quenched after 3 h. White solid (49.6 mg, 0.108 mmol, 74%), mp 81–83 °C (decomp); ^1H NMR (600 MHz, CDCl_3) δ 7.43 (d, $J = 7.4$ Hz, 2H), 7.38 (t, $J = 7.6$ Hz, 2H), 7.32 (t, $J = 7.3$ Hz, 1H), 7.26–7.20 (m, 3H), 7.08 (d, $J = 6.5$ Hz, 2H), 4.94 (d, $J = 1.9$ Hz, 1H), 3.53–3.48 (m, 3H), 3.44 (br s, 1H), 3.29 (d, $J = 12.2$ Hz, 1H), 1.52 (s, 9H), 1.51 (s, 9H); ^{13}C NMR (151 MHz, CDCl_3) δ 167.7, 166.9, 141.9, 137.4, 129.0, 128.4, 128.3, 127.7, 127.2, 126.1, 82.7, 82.2, 73.0,

57.0, 54.3, 38.6, 28.0 (2C). IR (thin film) ν 3459, 2979, 2359, 2341, 1731, 1455, 1369, 1254, 1140, 700 cm^{-1} . HRMS (ESI): Calcd For $\text{C}_{26}\text{H}_{34}\text{O}_5\text{SNa}^+$ ($[\text{M} + \text{Na}^+]$): 481.2025, found 481.2011. HPLC Chiralpak IA column, Hex/ $\text{PrOH} = 97:3$, flow rate = 1.0 mL/min, $\lambda = 210$ nm, t_R (major) 10.2 min, t_R (minor) 14.4 min. TLC (10/90 EtOAc/hexanes): $R_f = 0.27$. $[\alpha]_D^{25} = +18.4$ ($c = 2.0$, CHCl_3).

tert-Butyl (3S,4S,5S)-4-(isopropylthio)-2-oxo-5-phenyltetrahydrofuran-3-carboxylate (5a). A vial under an atmosphere of N_2 was charged with 4a (41.3 mg, 0.10 mmol, 1.0 equiv) and 1,4-dioxane (0.1 M). Then, 4 M HCl in 1,4-dioxane (0.1 M) was added dropwise at room temperature. The reaction was stirred for 5 h, then diluted with Et_2O and H_2O . The layers were separated, and the aqueous layer was extracted with Et_2O . The combined organic layers were dried with Na_2SO_4 and concentrated *in vacuo*. The crude material was then purified with flash column chromatography using 50/50 DCM/hexanes to give an off-white solid (25.5 mg, 0.075 mmol, 75%), mp 70–72 °C (decomp); ^1H NMR (600 MHz, CDCl_3) δ 7.43–7.39 (m, 3H), 7.29–7.28 (m, 2H), 5.81 (d, $J = 7.4$ Hz, 1H), 4.32 (t, $J = 7.7$ Hz, 1H), 3.68 (d, $J = 7.9$ Hz, 1H), 2.74–2.68 (m, 1H), 1.56 (s, 9H), 1.22 (d, $J = 6.6$ Hz, 3H), 1.18 (d, $J = 6.8$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 170.9, 165.9, 134.9, 129.0, 128.3, 126.6, 83.7, 82.5, 55.5, 46.8, 35.5, 27.9, 23.5, 23.2. IR (thin film) ν 3436, 1783, 1732, 1647, 1636, 1456, 1135, 1271, 1034, 978 cm^{-1} . HRMS (ESI): Calcd For $\text{C}_{18}\text{H}_{24}\text{O}_4\text{SNa}^+$ ($[\text{M} + \text{Na}^+]$): 359.1293, found 359.1285. HPLC Chiralpak IC column, Hex/ $\text{PrOH} = 96:4$, flow rate = 1.0 mL/min, $\lambda = 210$ nm, t_R (minor) 11.4 min, t_R (major) 12.6 min. TLC (10/90 EtOAc/hexanes): $R_f = 0.34$. $[\alpha]_D^{25} = -39.8$ ($c = 1.0$, CHCl_3).

tert-Butyl (3S,4S,5S)-4-(Benzylthio)-2-oxo-5-phenyltetrahydrofuran-3-carboxylate (5f). A vial under an atmosphere of N_2 was charged with 4f (41.3 mg, 0.10 mmol, 1.0 equiv) and 4 M HCl in 1,4-dioxane (2 mL). The reaction was stirred for 2 h, then diluted with Et_2O and H_2O . The layers were separated, and the aqueous layer was extracted with Et_2O . The combined organic layers were dried with Na_2SO_4 and concentrated *in vacuo*. The crude material was then purified with flash column chromatography using 50/50 DCM/hexanes to give an off-white solid (25.5 mg, 0.067 mmol, 67%), mp 94–96 °C (decomp); ^1H NMR (600 MHz, CDCl_3) δ 7.43–7.41 (m, 3H), 7.33 (t, $J = 7.2$ Hz, 2H), 7.29–7.27 (m, 3H), 7.21 (d, $J = 7.0$ Hz, 2H), 5.73 (d, $J = 7.0$ Hz, 1H), 4.11 (t, $J = 6.8$ Hz, 1H), 3.69 (d, $J = 6.7$ Hz, 1H), 3.49 (d, $J = 13.1$ Hz, 1H), 3.45 (d, $J = 13.1$ Hz, 1H), 1.55 (s, 9H); ^{13}C NMR (151 MHz, CDCl_3) δ 170.6, 165.6, 136.8, 134.7, 129.1, 128.9, 128.7, 128.3, 127.5, 126.5, 83.8, 82.3, 55.3, 47.8, 36.2, 27.9. IR (thin film) ν 3437, 1783, 1731, 1636, 1456, 1370, 1138, 1004, 979, 699 cm^{-1} . HRMS (ESI): Calcd For $\text{C}_{22}\text{H}_{24}\text{O}_4\text{SNa}^+$ ($[\text{M} + \text{Na}^+]$): 407.1293, found 407.1286. HPLC Chiralpak IC column, Hex/ $\text{PrOH} = 96:4$, flow rate = 1.0 mL/min, $\lambda = 210$ nm, t_R (major) 16.0 min, t_R (minor) 18.2 min. TLC (10/90 EtOAc/hexanes): $R_f = 0.29$. $[\alpha]_D^{25} = -49.3$ ($c = 1.0$, CHCl_3).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.8b00007.

Catalyst optimization and spectral data for all compounds (PDF)

Crystallographic data for 5f (CIF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: jsj@unc.edu.

ORCID

Jeffrey S. Johnson: 0000-0001-8882-9881

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The work described was supported by Award R35 GM118055 from the National Institute of General Medical Sciences. J.L.F. is an NSF Graduate Research Fellow. E.L.B. acknowledges support from the NSF REU program (CHE-1460874). We thank Dr. Brandie Ehrmann and Evan McConnell (UNC Department of Chemistry Mass Spectrometry Core Laboratory) for their assistance with mass spectrometry analysis and Blane Zavesky (UNC Department of Chemistry X-ray Structure Facility) for X-ray crystallographic analysis.

■ REFERENCES

- (1) (a) Jacob, C. *Nat. Prod. Rep.* **2006**, 23, 851–863. (b) Ondetti, M. A.; Rubin, B.; Cushman, D. W. *Science* **1977**, 196, 441–444. (c) Kim, J.; Ashenhurst, J. A.; Movassaghi, M. *Science* **2009**, 324, 238–241. (d) Nudelman, A. *The Chemistry of Optically Active Sulfur Compounds*; Gordon and Breach: New York, 1984. (e) *Sulphur-Containing Drugs and Related Organic Compounds*; Damani, L. A., Ed.; Wiley: New York, 1989.
- (2) (a) *Chiral Sulfur Ligands: Asymmetric Catalysis*; Pellissier, H., Ed.; RSC Publishing: Cambridge, U.K., 2009. (b) Gauthier, M. A.; Gibson, M. I.; Klok, H.-A. *Angew. Chem., Int. Ed.* **2009**, 48, 48–58. (c) Dondoni, A. *Angew. Chem., Int. Ed.* **2008**, 47, 8995–8997. (d) Hoyle, C. E.; Bowman, C. N. *Angew. Chem., Int. Ed.* **2010**, 49, 1540–1573. (e) Legros, J.; Dehli, J. R.; Bolm, C. *Adv. Synth. Catal.* **2005**, 347, 19–31. (f) Dénès, F.; Schiesser, C. H.; Renaud, P. *Chem. Soc. Rev.* **2013**, 42, 7900–7942. (g) Liebeskind, L. S.; Srogl, J. *Org. Lett.* **2002**, 4, 979–981.
- (3) For reviews of sulfa-Michael additions: (a) Enders, D.; Lüttgen, K.; Narine, A. A. *Synthesis* **2007**, 2007, 959–980. (b) Chauhan, P.; Mahajan, S.; Enders, D. *Chem. Rev.* **2014**, 114, 8807–8864. For selected recent examples: (c) Fang, X.; Wang, C.-J. *Chem. Commun.* **2015**, 51, 1185–1197. (d) Chatupheeraphat, A.; Liao, H.-H.; Mader, S.; Sako, M.; Sasai, H.; Atodiresei, I.; Rueping, M. *Angew. Chem., Int. Ed.* **2016**, 55, 4803–4807. (e) Guo, W.; Wu, B.; Zhou, X.; Chen, P.; Wang, X.; Zhou, Y.-G.; Liu, Y.; Li, C. *Angew. Chem., Int. Ed.* **2015**, 54, 4522–4526.
- (4) (a) Kowalczyk, R.; Wierzba, A. J.; Boratyński, P. J.; Bąkiewicz, J. *Tetrahedron* **2014**, 70, 5834–5842. For an example with acrylamide functionality instead of acrylate: (b) Zhao, F.; Zhang, W.; Yang, Y.; Pan, Y.; Chen, W.; Liu, H.; Yan, L.; Tan, C.-H.; Jiang, Z. *Adv. Synth. Catal.* **2011**, 353, 2624–2630.
- (5) Yang, J.; Farley, A. J. M.; Dixon, D. J. *Chem. Sci.* **2017**, 8, 606–610.
- (6) For the development of this catalyst family and recent applications, see: (a) Núñez, M. G.; Farley, A. J. M.; Dixon, D. J. *J. Am. Chem. Soc.* **2013**, 135, 16348–16351. (b) Goldys, A. M.; Dixon, D. J. *Macromolecules* **2014**, 47, 1277–1284. (c) Goldys, A. M.; Núñez, M. G.; Dixon, D. J. *Org. Lett.* **2014**, 16, 6294–6297. (d) Farley, A. J. M.; Sandford, C.; Dixon, D. J. *J. Am. Chem. Soc.* **2015**, 137, 15992–15995. (e) Robertson, G. P.; Farley, A. J. M.; Dixon, D. J. *Synlett* **2016**, 27, 21–24. (f) Horwitz, M. A.; Zavesky, B. P.; Martinez-Alvarado, J. I.; Johnson, J. S. *Org. Lett.* **2016**, 18, 36–39. (g) Shi, H.; Michaelides, I. N.; Darses, B.; Jakubec, P.; Nguyen, Q. N. N.; Paton, R. S.; Dixon, D. J. *J. Am. Chem. Soc.* **2017**, 139, 17755–17758.
- (7) Horwitz, M. A.; Fulton, J. L.; Johnson, J. S. *Org. Lett.* **2017**, 19, 5783–5785.
- (8) When a large excess (5 equiv) of substituted benzyl thiol was employed, a new side product was observed (the alkane resulting from reduction of the alkene in **1**), and enantioselectivity decreased significantly. We hypothesize that the excess thiol racemizes the conjugate addition product *via* formation of the disulfide. The resulting enolate (or equivalent) can then either attack the disulfide to form the racemic product or become protonated to give the observed reduction product. Aryl thiols were unsuccessful in this reaction as racemization proved unavoidable.
- (9) (a) Hoffmann, R. W. *Synthesis* **2004**, 2004, 2075–2090. (b) Horwitz, M. A.; Johnson, J. S. *Eur. J. Org. Chem.* **2017**, 2017, 1381–1390.
- (10) (a) Kano, S.; Yokomatsu, T.; Shibuya, S. *J. Chem. Soc., Chem. Commun.* **1978**, 0, 785–786. (b) Shimagaki, M.; Maeda, T.; Matsuzaki, Y.; Hori, I.; Nakata, T.; Oishi, T. *Tetrahedron Lett.* **1984**, 25, 4775–4778.
- (11) CCDC 1587179 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Centre via www.ccdc.cam.ac.uk/data_request/cif.